You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Boehringer Ingelheim
Harvard Business School
Mallinckrodt
Moodys

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

PITAVASTATIN CALCIUM - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for pitavastatin calcium and what is the scope of patent protection?

Pitavastatin calcium is the generic ingredient in two branded drugs marketed by Kowa Co, Aurobindo Pharma Ltd, Mylan, Orient Pharma Co Ltd, and Sawai Usa, and is included in five NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Pitavastatin calcium has sixty-two patent family members in nineteen countries.

There are fifteen drug master file entries for pitavastatin calcium. One supplier is listed for this compound. There is one tentative approval for this compound.

Recent Clinical Trials for PITAVASTATIN CALCIUM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jun TaoPhase 4
Sun Yat-sen UniversityPhase 4
Chungnam National University HospitalPhase 4

See all PITAVASTATIN CALCIUM clinical trials

Generic filers with tentative approvals for PITAVASTATIN CALCIUM
Applicant Application No. Strength Dosage Form
  Start Trial  Start TrialEQ 4MG BASETABLET;ORAL
  Start Trial  Start TrialEQ 2MG BASETABLET;ORAL
  Start Trial  Start TrialEQ 1MG BASETABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for PITAVASTATIN CALCIUM
Paragraph IV (Patent) Challenges for PITAVASTATIN CALCIUM
Tradename Dosage Ingredient NDA Submissiondate
LIVALO TABLET;ORAL pitavastatin calcium 022363 2013-08-05

US Patents and Regulatory Information for PITAVASTATIN CALCIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-001 Aug 3, 2009 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-001 Aug 3, 2009 AB RX Yes No   Start Trial   Start Trial   Start Trial
Mylan PITAVASTATIN CALCIUM pitavastatin calcium TABLET;ORAL 206070-003 Apr 4, 2019 DISCN No No   Start Trial   Start Trial   Start Trial
Sawai Usa PITAVASTATIN CALCIUM pitavastatin calcium TABLET;ORAL 205955-003 Feb 3, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
Sawai Usa PITAVASTATIN CALCIUM pitavastatin calcium TABLET;ORAL 205955-002 Feb 3, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PITAVASTATIN CALCIUM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-001 Aug 3, 2009   Start Trial   Start Trial
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-002 Aug 3, 2009   Start Trial   Start Trial
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-003 Aug 3, 2009   Start Trial   Start Trial
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-003 Aug 3, 2009   Start Trial   Start Trial
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-001 Aug 3, 2009   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
McKinsey
Dow
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.